GlobeNewsWire
05 Jun 2026, 12:45 UTC · 23w ago
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Impact · against what's priced in
Vivos Therapeutics is taking necessary steps to avoid delisting by exchanging $4.5 million of debt for equity. While this improves the balance sheet and liquidity, the benefit is partially offset by the requirement for additional equity financing, which introduces dilution risk.
- VVOS+0.30
No priced-in read yet





